ScandiBio Therapeutics AB Announces Initiation of Phase 3 Clinical Trial of Combined Metabolic Activators (CMA) for Alzheimer's Disease
ScandiBio Therapeutics AB Initiates Phase 3 Clinical Trial for Alzheimer's Disease Alzheimer's disease is the most common cause of dementia, leading to memory loss and cognitive impairment…